CSBio CSBio

X
[{"orgOrder":0,"company":"4D Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"4D Pharma Announces FDA Clearance of IND Application for Live Biotherapeutics MRx0005 and MRx0029 for the Treatment of Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"4D Pharma"},{"orgOrder":0,"company":"GSK","sponsor":"SciNeuro Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SciNeuro Pharmaceuticals Announces a License and Option Agreement with GSK to Progress Development of Novel Therapies for CNS Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"UNITED KINGDOM","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Undisclosed","graph2":"GSK"},{"orgOrder":0,"company":"BenevolentAI","sponsor":"The Sheffield Institute for Translational Neuroscience","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BenevolentAI Progresses BEN-34712 for the Potential Treatment of ALS into IND-Enabling Studies","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"BenevolentAI"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tiziana Life Sciences Announces FDA IND Clearance of Intranasal Foralumab for the Treatment of Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Tiziana Life Sciences"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Tiziana’s intranasal TZLS-401 (foralumab), is the only fully human anti-CD3 mAb and has demonstrated a favorable safety profile and clinical response in patients with alzheimer’s disease.

            Lead Product(s): Foralumab

            Therapeutic Area: Neurology Product Name: TZLS-401

            Highest Development Status: IND Enabling Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 15, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            BEN-34712 is an oral, potent and selective brain penetrant RARɑβ (retinoic acid receptor alpha beta) biased agonist and will now enter investigational new drug (IND)-enabling studies for amyotrophic lateral sclerosis.

            Lead Product(s): BEN-34712

            Therapeutic Area: Neurology Product Name: BEN-34712

            Highest Development Status: IND Enabling Product Type: Small molecule

            Partner/Sponsor/Collaborator: The Sheffield Institute for Translational Neuroscience

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 03, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            GSK

            Contact Supplier
            • Deals

            Details:

            Under the agreement, SciNeuro will receive a worldwide license to intellectual property covering certain GSK Lp-PLA2 inhibitors including SNP318 and will be responsible for their further development through clinical proof-of-concept (PoC).

            Lead Product(s): SNP318

            Therapeutic Area: Neurology Product Name: SNP318

            Highest Development Status: IND Enabling Product Type: Undisclosed

            Partner/Sponsor/Collaborator: SciNeuro Pharmaceuticals

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement June 01, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            IND clearance marks the expansion of the comany's pipeline single strain Live Biotherapeutics of MRx0005 and MRx0029 in development for the treatment of neurodegenerative conditions such as Parkinson’s disease via the gut-brain axis.

            Lead Product(s): MRx0005

            Therapeutic Area: Neurology Product Name: MRx0005

            Highest Development Status: IND Enabling Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 22, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY